CEMIPLIMAB*
PD-1 Antibody
Cancer
A POWERFUL RESEARCH AND
DEVELOPMENT ENGINE
Our robust pipeline of investigational product candidates strives to address many serious medical conditions including asthma, pain, cancer and infectious diseases.
-
Phase 1 Trials
REGN1979
CD20 X CD3 AntibodyCancerCEMIPLIMAB + REGN1979
PD-1 Antibody + CD20 X CD3 AntibodyCancerREGN3767
LAG-3 AntibodyCancerCEMIPLIMAB + REGN3767
PD-1 Antibody + LAG-3 AntibodyCancerREGN5458*
BCMA X CD3 AntibodyCancerREGN4018*
MUC16 X CD3 AntibodyCancerCEMIPLIMAB + REGN4018*
PD-1 Antibody + MUC16 X CD3 AntibodyCancerREGN4659
CTLA4 AntibodyCancerREGN3048-3051
Middle Eastern Respiratory Coronavirus AntibodyMERS-CoV infectionPOZELIMAB
C5 AntibodyParoxysmal nocturnal hemoglobinuriaREGN4461
LEPR AntibodyLipodystrophy and obesityREGN5069
GFRα3 AntibodyPain -
Phase 2 Trials
CEMIPLIMAB*
PD-1 AntibodyBasal cell carcinomaDUPILUMAB*
IL-4R AntibodyGrass allergy, peanut allergySARILUMAB*
IL-6R AntibodyPolyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritisEVINACUMAB
ANGPTL-3 AntibodyRefractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemiaREGN1908-1909
Fel d 1 AntibodyCat allergyGARETOSMAB
Activin A AntibodyFibrodysplasia Ossificans Progressiva (FOP)REGN3500*
IL-33 AntibodyAtopic dermatitis, asthma, chronic obstructive pulmonary disease (COPD) -
Phase 3 Trials
ALIROCUMAB*
PCSK9 AntibodyHomozygous familial hypercholesterolemia (HoFH) in adults and pediatrics, heterozygous familial hypercholesterolemia in pediatricsCEMIPLIMAB*
PD-1 AntibodyNon-small cell lung cancer, cervical cancerDUPILUMAB*
IL-4R AntibodyAtopic dermatitis in pediatrics, asthma in pediatrics, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD)SARILUMAB*
IL-6R AntibodyPolymyalgia rheumatica, giant cell arteritisEVINACUMAB
ANGPTL-3 AntibodyHomozygous familial hypercholesterolemia (HoFH)REGN-EB3 (REGN3470-3471-3479)
Ebola Virus AntibodyEbola virus infectionFASINUMAB†
NGF AntibodyChronic pain from osteoarthritis of the knee or hip
Trials Footnotes
* in collaboration with Sanofi
† in collaboration with Teva and Mitsubishi Tanabe
This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.